Krystal Biotech falls as Q1 revenue misses estimates

Krystal Biotech

06/05/2024 14:31

** Shares of gene therapy developer Krystal Biotech  KRYS.O 
fall 8.7% at $147  
    ** Co reports Q1 product revenue of $45.2 mln, missing
analysts' estimate of $47.4 mln- LSEG data  
    ** Says co continues to anticipate $150 mln to $175 mln of
R&D and SG&A expenses for the year 
    ** KRYS says cash, cash equivalents and investments totaled
$622.3 mln as of March 31, 2024
    ** Up to last close, stock had risen 29.9% YTD 

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))